Aryl triazines as LPAAT-β inhibitors and uses thereof

Details Aryl triazines as LPAAT-β inhibitors and uses thereof Aryl triazines as LPAAT-β inhibitors and uses thereof

2007-08-06

2009-11-17

Balasubramanian, Venkataraman (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C544S206000, C544S216000, C514S245000

Reexamination Certificate

active

07618968

ABSTRACT:
The invention relates to aryl triazines and uses thereof, including to inhibit lysophosphatidic acid acyltransferase β (LPAAT-β) activity and/or proliferation of cells such as tumor cells.

REFERENCES:
patent: 3119823 (1964-01-01), Shapiro
patent: 3933814 (1976-01-01), Haberkorn et al.
patent: 3948893 (1976-04-01), Aichinger et al.
patent: 3966725 (1976-06-01), Reisdorff et al.
patent: 4219552 (1980-08-01), Haberkorn et al.
patent: 4499269 (1985-02-01), Bennion et al.
patent: 5102927 (1992-04-01), Rody et al.
patent: 5260362 (1993-11-01), Rody et al.
patent: 5545836 (1996-08-01), Reinehr et al.
patent: 5702717 (1997-12-01), Cha et al.
patent: 5856331 (1999-01-01), Bursten
patent: 5962453 (1999-10-01), Ueda et al.
patent: 6004985 (1999-12-01), Kochanny et al.
patent: 6150360 (2000-11-01), Daeyaert et al.
patent: 6150362 (2000-11-01), Henkin et al.
patent: 6150382 (2000-11-01), Kochanny et al.
patent: 6166014 (2000-12-01), Kochanny et al.
patent: 6193960 (2001-02-01), Metzger et al.
patent: 6288228 (2001-09-01), Henkin et al.
patent: 7291616 (2007-11-01), Bhatt et al.
patent: 1200314 (1965-09-01), None
patent: 2226474 (1973-02-01), None
patent: 525 262 (1993-02-01), None
patent: 1321624 (1963-03-01), None
patent: 963814 (1964-07-01), None
patent: 48-28486 (1973-04-01), None
patent: 49-69688 (1974-07-01), None
patent: 274102 (1970-04-01), None
patent: WO 91/11465 (1991-08-01), None
patent: WO 00/25780 (2000-05-01), None
patent: WO 01/25220 (2001-04-01), None
patent: WO 02/36578 (2002-05-01), None
Rudenko et al, Ukrainski Khimcheski Zhurnal (Russian Edition), 58(7), 585-587, 1992; CA 118: 38890, 1993.
Bennett, J.C. et al. (eds.), Cecil Textbook of Medicine, 20thEdition, W.B. Saunders Company, Philadelphia, PA, 1996, pp. 1004-1010.
Bonham, L. et al., “Lysophosphatidic acid acyltransferase-β: a novel target for induction of tumour cell apoptosis,”Expert Opin. Ther. Targets 7(5): 643-661, 2003.
Britten and Kohne, “Repeated Sequences in DNA,” Science 161(3841): 529-540, Aug. 9, 1968.
Brodskii et al., “The mechanism underlying the action of secondary aromatic amine- type antioxidants and their ether on the radiation oxidation of N-butylpropionamide and polycaproamide,” Chemical Abstracts, Accession No. 69:3284, 1968.
Budesinsky et al., “Substituted 2,4-diamino-6-phenyl-1,3,5-triazines,” Chemical Abstracts, Accession No. 97:6328, 1982.
Burmistrov et al., “6-Amino-4-arylamino-2-(o-hydroxyphenyl) triazines,” Chemical Abstracts, Accession No. 61:47941, 1964.
Bursten et al., “Interleukin-1 Rapidly Stimulates Lysophosphatidate Acyltransferase and Phosphatidate Phosphohydrolase Activities in Human Mesangial Cells,” Journal of Biological Chemistry 266(31): 20732-20743, Nov. 5, 1991.
Bursten et al., “Lipid A activation of glomerular mesangial cells: mimicry of the bioactive lipid, phophatidic acid,”American Journal of Physiology 262(2): C328-C338, Feb. 1992.
Chemical Abstracts Database Online. Accession No. 1969:439618, 1969.
Chemical Abstracts Database Online. Accession No. 1970:456484, 1970.
Chemical Abstracts Database Online. Accession No. 1973:159683, 1973.
Chemical Abstracts Database Online. Accession No. 1974:403898, 1974.
Chemical Abstracts Database Online. Accession No. 1974:437076, 1974.
Chemical Abstracts Database Online. Accession No. 1974:536188, 1974.
Chemical Abstracts Database Online. Accession No. 1974:569925, 1974.
Chemical Abstracts Database Online. Accession No. 1974:82903, 1974.
Chemical Abstracts Database Online. Accession No. 1984:103965, 1984.
Chemical Abstracts Database Online. Accession No. 1994:557609, 1994.
Chen, C. et al., “A Convenient Synthetic Method for Trisubstituted s-Triazines,” Chemical Abstracts, Accession No. 124:146076, 1995.
Eberhardt et al., “Human Lysophosphatidic Acid Acyltransferase,” Journal of Biological Chemistry 272(32): 20299-20305, Aug. 8, 1997.
Elkafrawy, A.F. et al., “Synthesis and reaction of some 4-aryl-2-benzylthio-1, 6-dihydro-6-thiono-1,3,5-triazines,” Chemical Abstracts, Accession No. 115:279963, 1991.
English, D., “Phosphatidic acid: A lipid messenger involved in intracellular and extracellular signaling,” Cell Signal 8(5): 341-347, 1996.
Fong and Engleman, “Dendritic Cells in Cancer Immunotherapy,” Annual Review of Immunology 18: 245-273, 2000.
Hasan, J. et al., “VEGF antagonists,”Expert Opin. Biol. Ther. 1(4): 703-718, 2001.
Hoess and Abremski, “The Cre-lox Recombination System,” Nucleic Acids and Molecular Biology 4: 99-109, 1990.
Imamura et al, “Induction of in vitro tumor cell invasion of cellular monolayers by lysophosphatidic acid or phospholipase D,”Biochemical and Biophysical Research Communications 193(2): 497-503, Jun. 15, 1993.
Kester, M., “Platelet-Activating Factor Stimulates Phosphatidic Acid Formation in Cultured Rat Mesangial Cells: Roles of Phospholipase D, Diglyceride Kinase, and De Novo Phospholipid Synthesis,” Journal of Cellular Physiology 156: 317-325, 1993.
Köhler and Milstein, “Continuous cultures of fused cells secreting antibody of predefined specificity,” Nature 256: 495-497, Aug. 7, 1975.
Kume and Shimizu, “cDNA Cloning and Expression of Murine 1-Acyl-sn-glycerol-3-phosphate Acyltransferase,” Biochemical and Biophysical Research Communications 237(3): 663-666, Aug. 28, 1997.
Leung et al., “Molecular Cloning of Two Alternatively Spliced Forms of Human Phosphatidic Acid Phosphatase cDNAs that Are Differentially Expressed in Normal and Tumor Cells,” DNA and Cell Biology 17(4): 377-385, Apr. 1998.
Losman et al., “Baboon anti-idiotype antibodies mimic a carcinoembryonic antigen epitope,” Int. J. Cancer 46(2): 310-314, Aug. 15, 1990.
Martin et al., “Increased concentrations of phosphatidate, diacylglycerol and ceramide in ras- and tyrosine kinase (fps)-transformed fibroblasts,” Oncogene 14(13):1571-1580, Apr. 3, 1997.
Michalik, M. et al., “Synthesis of nitrogen-containing heterocycles,” Chemical Abstracts, Accession No. 79:18680, 1973.
Miller and Rosman, “Improved Retroviral Vectors for Gene Transfer and Expression,” BioTechniques 7(9): 980-EOA, Oct. 1989.
Moolenaar, W.H., “Lysophosphatidic Acid, a Multifunctional Phospholipid Messenger,”Journal of Biological Chemistry 270(22): 12949-12952, Jun. 2, 1995.
Moussa, G.E.M. et al., “Some reactions on 4-aryl-2-substituted amino-1,6-dihydro-6-thioxo-1,3,5 triazines,” Chemical Abstracts, Accession No. 113:59112, 1990.
Orlandi et al., “Cloning immunoglobulin variable domains for expression by the polymerase chain reaction,” Proc. Natl. Acad. Sci. USA 86(10): 3833-3837, May 1989.
Pegram, M.D. et al, “Combined biological therapy of breast cancer using monoclonal antibodies directed against HER2
eu protein and vascular endothelial growth factor,”Semin. Oncol. 29(3 Suppl. 11): 29-37, 2002.
Pitts et al., “Rapid Synthesis of Triazine Inhibitors of Inosine Monophosphate Dehydrogenase,” Bioorganic & Medicinal Chemistry Letters 12: 2137-2140, 2002.
Rizzo et al., “The Recruitment of Raf-1 to Membranes Is Mediated by Direct Interaction with Phosphatidic Acid and Is Independent of Association with Ras,” Journal of Biological Chemistry 275(31): 23911-23918, Aug. 4, 2000.
Sauer, B., “Inducible Gene Targeting in Mice Using the Cre/lox System,” Methods: A Companion to Methods in Enzymology 14(4): 381-392, Apr. 1998.
Schreurs et al., “Dendritic Cell-Based Vaccines: From Mouse Models to Clinical Cancer Immunotherapy,” Critical Reviews in Oncogenesis 11(1): 1-17, 2000.
Shapiro, S.L. et al., “Guanamines. VIII. 6-(Substituted-phenyl) guanamines,” Chemical Abstracts, Accession No. 56:60602, 1962.
Sharp et al., “Viral DNA in Transformed Cells. I. A Study of the Sequences of Adenovirus 2 DNA in a Line of Transformed Rat C

Affiliated with

Also associated with

Rating

Aryl triazines as LPAAT-β inhibitors and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Aryl triazines as LPAAT-β inhibitors and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Aryl triazines as LPAAT-β inhibitors and uses thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4086716